Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term renal cell carcinoma. Found 29 abstracts

no pagination
McIntosh AG, Parker DC, Egleston BL, Uzzo RG, Haseebuddin H, Joshi SS, Viterbo R, Greenberg RE, Chen DY, Smaldone MC, Kutikov A. Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function. BJU international. 2019 May 30;124(6):999-1005.
Naito S, Ichiyanagi O, Ito H, Kabasawa T, Kanno H, Narisawa T, Fukuhara H, Yagi M, Kurota Y, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Kato T, Makhov P, Kolenko VM, Yamakawa M, Tsuchiya N. Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma. Oncol Lett. 2019 Apr;17(4):3910-8.   PMCID: PMC6403496
Narayan V, Puligandla M, Haas NB, Subramanian P, DiPaola RS, Uzzo R. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial. J Urol. 2019 Jan;201(1):62-8.   PMCID: PMC6614871
Nicolas E, Demidova EV, Iqbal W, Serebriiskii IG, Vlasenkova R, Ghatalia P, Zhou Y, Rainey K, Forman AF, Dunbrack RL, Golemis EA, Hall MJ, Daly MB, Arora S. Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma. Molecular genetics & genomic medicine. 2019 Mar;7(3):e556.   PMCID: PMC6418363
Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 2019 Apr 05;125(14):2400-8.   PMCID: PMC6602847
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Li P, Wong YN, Jahnke J, Pettit AR, Doshi JA. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma. Cancer medicine. 2018 Jan;7(1):75-86.   PMCID: PMC5774001
Mehrazin R, Dulaimi E, Uzzo RG, Devarjan K, Pei J, Smaldone MC, Kutikov A, Testa JR, Al-Saleem T. The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology. 2018 Jan;10(1):3-10.   PMCID: PMC5761913
Ristau BT, Handorf EA, Cahn DB, Kutikov A, Uzzo RG, Smaldone MC. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base. Cancer. 2018 Oct;124(19):3839-48.
Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2018 Jan;199(1):53-9.   PMCID: PMC5800986
Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU international. 2017 Dec;120(6):782-92.
Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, Chen DY, Greenberg RE, Kutikov A, Viterbo R, Uzzo RG, Testa JR. Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features. J Urol. 2016 Apr;195(4 Pt 1):852-8.   PMCID: PMC4871784
Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)- tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016 Jul;27(7):1304-11.
Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Rathmell WK, Wood CG, Tannir NM. Management and Outcomes of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. BJU international. 2016 Nov 08;.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Shaikh T, Handorf EA, Murphy CT, Kutikov A, Uzzo RG, Hallman M, Horwitz EM, Smaldone MC. Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology. 2015 Dec;86(6):1165-73.
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Chen PR, Balachandran S. Development of interferon gamma-based immunocytokines targeting renal cancer. Oncoimmunology. 2013 Jul;2(7):e24964.   PMCID: PMC 3782162
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expert Opinion on Biological Therapy. 2010 Feb;10(2):273-9.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term renal cell carcinoma

renal cell carcinoma kidney cancer overall survival nephrectomy radical nephrectomy drug therapy Kidney Neoplasms metastatic randomized controlled trial nomogram Kidney kidney i clinical-trials immune checkpoint blockade mAbs comparative effectiveness Child Non-clear cell III TRIAL 4ebp1 mRCC efficacy biopsy necrosis germline surveillance SEA phase 2 nivolumab renal medullary carcinoma c-MYC antitumor-activity patterns of care clinical trials Cd70 Male 8q ramucirumab microarray analysis pancreatic cancer Renal Cell Carcinoma prognosis interest Female succinate dehydrogenase complex cancer Kaplan-Meier Estimate dose-escalation immunotherapy variants of uncertain significance monoclonal #KidneyCancer Cost sharing Infrared Rays metastatic renal cell carcinoma targeted therapies single nucleotide polymorphism SELECTION Oncology chronic kidney disease Adult epidemiology cytotoxic T-lymphocyte associated protein 4 vascular endothelial growth factor receptor - tyrosine kinase inhibitor CANCER Middle Aged TUMORS prognostic factor GROWTH surgery phase-i SUNITINIB NSCLC cytokines monoclonal-antibody superantigen PD-1 inhibitor pathology inhibitor chromosome aberrations mortality sunitinib Rip1 SORAFENIB Raman spectroscopy erlotinib Young Adult estimated glomerular filtration rate chemotherapy angiogenesis Medullary Carcinoma #Kcsm Medicare AUA guidelines ipilimumab Treatment Outcome specialty drugs cancer risk cytology interferon lymphadenectomy growth-factor receptor gefitinib overdose control tumor-therapy national cancer database partial nephrectomy rfb4(dsfv)-pe38 adjuvant therapy Retrospective Studies cytogenetic analysis renal-cell Adolescent naptumomab immunotoxin programmed death 1 5t4 oncofetal antigen bevacizumab carcinoma cytokine phosphorylated 4EBP1 antiangiogenic agents radiotherapy renal medullary carcinoma (RMC) necroptosis recurrence free survival PROGNOSTIC-FACTORS relapse diagnosis Nephrectomy antibody immunocytokines T cell Rmc superantigen fusion proteins Raman Spectrum Analysis Vegf adjuvant pharmacokinetics proto-oncogene Rcc variant interaction BEVACIZUMAB tissue diagnosis
Last updated on Friday, December 06, 2019